We demonstrated that simplification of basal‐bolus or premixed insulin regimens can be performed with an FRC successfully in adults with type 2 diabetes who have an HbA1c ≤ 7.5% (58 mmol/mol), are treated with relatively low insulin doses (TDD ≤ 0.6 IU/kg and TDD ≤ 70 IU/day) and have a detectable (≥1.1 ng/ml) random, non‐fasting serum C‐peptide level indicating some degree of preserved beta‐cell function. This evidence concerns the gene INS and type 2 diabetes mellitus.